Behavioral and Neural Phenotypes of Primary Dysmenorrhea in Adolescents

The study will use primary dysmenorrhea (PD; menstrual pain without an identified organic cause) as a model to examine biomarkers associated with menstrual and non-menstrual bodily pain in adolescent girls, ages 13-19. Participants will undergo extensive phenotyping including pain inhibition testing and multimodal neuroimaging to obtain indices brain structure and function at baseline and 12 months later. Menstrual pain severity and non-menstrual bodily pain will be assessed monthly for 24 months. Aims of the study are: 1) to identify the central mechanisms of PD using measures of pain inhibition and brain structure and connectivity of sensorimotor, default, emotional arousal, and salience networks, 2) to determine deficits in pain inhibition and alterations in brain structure and network connectivity that predict the one-year developmental trajectories of menstrual pain and non-menstrual bodily pain, and 3) to identify the dynamic relationship between alterations in pain inhibition and brain structure and connectivity with symptom change in menstrual pain and non-menstrual bodily pain. We hypothesize that deficits in endogenous pain inhibition and alterations in brain structure, connectivity, and function of regional networks will be positively associated with menstrual pain severity ratings at baseline and predict the trajectory of menstrual and non-menstrual bodily pain over 2 years. The results are expected to identify specific mechanisms and characteristics that predict the transition from acute/cyclical pain to persistent or chronic pain, which will support the development of therapies to prevent the transition from recurrent to chronic pain in adulthood.

Study Overview

• Status: Active, not recruiting
• Conditions: Primary Dysmenorrhea
• Intervention / Treatment: Behavioral: Quantitative Sensory Testing; Other: fMRI

• Study Type: Interventional
• Enrollment (Actual): 164
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Laura Seidman; Phone Number: (617) 855-2746; Email: LCSeidman@mclean.harvard.edu

Study Locations

• United States
  • Massachusetts
    • Belmont, Massachusetts, United States, 02478
      • McLean Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 13 years to 19 years (Child, Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

1. Female aged 13-19 years
2. Self-reported menstrual cycle averaging 22-35 days
3. Regular menstrual cycles for at least 6 months
4. Access to a smartphone or email
5. Right handed
6. Body Mass Index (BMI) of 35 or less
7. Able to read and understand English
8. Ability and willingness to provide written informed assent/consent
9. Availability of a parent to provide written parental permission (for participants under age 18)

Exclusion Criteria:

1. Use of oral contraceptives or any exogenous hormones in the previous 3 months prior to participation
2. Presence of factors indicative of secondary dysmenorrhea (e.g., self-reported presence of persistent pelvic pain throughout the month)
3. Diagnosis of chronic pain condition (e.g., Irritable bowel syndrome (IBS), functional abdominal pain, interstitial cystitis/painful bladder syndrome)
4. Current self-reported severe depression, bipolar disorder, panic disorder, or ADHD, or current treatment for these conditions
5. Diagnosis of an eating disorder within the last 6 months
6. Current or past diagnosis of any psychotic disorder
7. Currently pregnant
8. Self-reported weekly use of alcohol, cannabis, and/or other illegal substances
9. Use of stimulants (including methamphetamine and/or medications for the treatment of ADHD) or opioids in the previous 3 months. Participants who use other analgesics will be included but will be requested to not take these analgesics within the previous 24 hours of the laboratory session
10. History of pelvic inflammatory disease or sexually transmitted disease
11. Acute illness or injury that would potentially impact pain task performance (e.g., fever, flu symptoms) or that affect sensitivity of the extremities (e.g., Reynaud's disease). Potential participants who are being treated for cardiovascular disease(s) will be included pending discussion with the participant's primary physician
12. Developmental delay, diagnosis of autism, or significant cognitive impairment that may preclude understanding of study procedures
13. Presence of certain ferromagnetic appliance or implants (braces, retainers, spacers, wires, screws, etc.) in the mouth or any other body part that may be a contraindication for the magnetic resonance imaging (MRI) scanner
14. Significant fear of enclosed places (claustrophobia)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Other
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: fMRI and laboratory pain induction	Behavioral: Quantitative Sensory Testing; Quantitative sensory testing (QST) consisting of 4 pain induction and sensory sensitivity tasks (i.e., pressure applied to the thumbnail, arms, shoulders, and lower abdomen, a cold water task, and one video-watching task).; Other: fMRI; Functional magnetic resonance imaging (fMRI) session consisting of structural and functional brain scans.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Menstrual pain	Rating of average pain during the first two days of the most recent menstrual period on a 0 (no pain) to 10 (worst pain possible) numeric rating scale.	Baseline
Change in menstrual pain from baseline to 12-months post baseline	Change in the rating of average pain during the first two days of the most recent menstrual period on a 0 (no pain) to 10 (worst pain possible) numeric rating scale.	At baseline and 12 months after baseline
Change in bodily pain from baseline to 12-months post baseline	Change in the number of bodily locations endorsed as painful during the prior month.	At baseline and 12 months after baseline
Pressure pain sensitivity (PPS)	The pain rating [on a 0 (no pain) to 100 (worst pain possible) numeric rating scale] of a 5-second, 2.0 kg/cm2 application of pressure to the right thumbnail bed.	At baseline
Pressure pain tolerance (PPT)	The last rated pressure delivered in a series of increasing pressure applications to the right thumbnail bed. Each application of pressure lasts for 5 seconds. The pressure sequence is terminated when the participant reaches their individual tolerance and decides to stop, when the participant reaches the safety maximum amount of pressure, or when the participant rates the pressure >=80 on a 0 (no pain) to 100 (worst pain possible) numeric rating scale.	At baseline
Trapezius pressure pain threshold (TPPTh)	The amount of pressure, applied by a pressure algometer to the participant's trapezius muscle, needed for the pressure stimulus to first feel painful to the participant.	At baseline
Conditioned pain modulation (CPM)	Conditioned pain modulation (CPM) assesses pain inhibition. CPM is calculated as the change in the TPPTh between when the pressure is applied by itself (test stimulus) and when it is applied while the participant's hand is submerged in cold water (conditioning stimulus).	At baseline
Gray matter volume	Gray matter regional volume and surface area will be measured from images obtained during the fMRI session.	At baseline
White matter fiber tract values	Obtained from fiber tracking using images obtained during diffusion tensor imaging (DTI). Values represent anatomical connectivity of cortical and subcortical brain regions.	At baseline
Resting state networks	Calculated from images obtained during resting state fMRI. Region-to-region connectivity indices are obtained by correlating fMRI time series corrected for physiological noise and motion. Region-to-region connectivity strength of the regions of interest (i.e., salience, sensorimotor, emotional arousal, and default mode networks) will be assessed for each participant.	At baseline

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in menstrual pain from 12-months post baseline to 24-months post baseline	Change in the rating of average pain during the first two days of the most recent menstrual period on a 0 (no pain) to 10 (worst pain possible) numeric rating scale.	12 months after baseline and 24 months after baseline
Change in bodily pain from 12-months post baseline to 24-months post baseline	Change in the number of bodily locations endorsed as painful during the prior month.	12 months after baseline and 24 months after baseline
Salivary pro-inflammatory cytokines	Assessment of pro-inflammatory cytokines found in the saliva (e.g., IL-1 Beta, IL-6, IL-8, TNF-Alpha)	Three time points during each of two study visits: during questionnaire completion (approx. 20 min. after arrival), immediately after the imaging session (approx. 90 min. after arrival), and following the final pain task (approx. 120 min after arrival)
Trapezius pressure pain threshold (TPPTh)	The amount of pressure, applied by a pressure algometer to the participant's trapezius muscle, needed for the pressure stimulus to first feel painful to the participant.	12 months after baseline
Change in conditioned pain modulation (CPM) from baseline to 12-months post baseline	Alterations in pain inhibition will be assessed via the direction of the change (i.e., improvement in pain inhibition, worsening of pain inhibition, and stable pain inhibition) as well as the magnitude of the change.	At baseline and 12 months after baseline
Change in pressure pain sensitivity (PPS) from baseline to 12-months post baseline	Change in the pain rating [on a 0 (no pain) to 100 (worst pain possible) numeric rating scale] of a 5-second, 2.0 kg/cm2 application of pressure to the right thumbnail bed.	At baseline and 12 months after baseline
Change in pressure pain tolerance (PPT) from baseline to 12-months post baseline	Change in the PPT described above between baseline and 12-months post baseline.	At baseline and 12 months after baseline
Change in gray matter volume from baseline to 12-months post baseline	Change in the gray matter regional volume and surface area obtained from images obtained during the fMRI session.	At baseline and 12 months after baseline
Change in white matter fiber tract values from baseline to 12-months post baseline	Change in the DTI-produced fiber tracking values, which represent anatomical connectivity of cortical and subcortical brain regions.	At baseline and 12 months after baseline
Change in resting state networks	Change in region-to-region connectivity strength of the regions of interest (i.e., salience, sensorimotor, emotional arousal, and default mode networks).	At baseline and 12 months after baseline

Collaborators and Investigators

• Sponsor: Mclean Hospital
• Collaborators: Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
• Investigators: Principal Investigator: Laura Payne, PhD, McLean Hospital

Study record dates

Study Major Dates

• Study Start (Actual): December 14, 2020
• Primary Completion (Estimated): December 1, 2025
• Study Completion (Estimated): December 1, 2025

Study Registration Dates

• First Submitted: December 2, 2020
• First Submitted That Met QC Criteria: December 22, 2020
• First Posted (Actual): December 28, 2020

Study Record Updates

• Last Update Posted (Actual): October 24, 2023
• Last Update Submitted That Met QC Criteria: October 23, 2023
• Last Verified: October 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Pathologic Processes; Pain; Neurologic Manifestations; Menstruation Disturbances; Pelvic Pain; Dysmenorrhea
• Other Study ID Numbers: 2019P001729

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No